Clinical Trials Logo
  1. Home
  2. Tuberculosis
  3. NCT02627209
  4. Details
NCT02627209 Clinical Trial

The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis

Tuberculosis Clinical Trial

— uveitis  

Official title:
Non-infectious and Infectious Uveitis Diagnosis

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02627209
Other study ID # DGH-070
Secondary ID
Status Recruiting
Phase N/A
First received November 26, 2015
Last updated December 9, 2015
Start date June 2014
Est. completion date January 2017

Study information
Verified date December 2015
Source Dünyagöz Hospital
Contact ozlem sahin, MD
Phone 90-537-5523064
Email ozlem1158@yahoo.com
Is FDA regulated No
Health authority Turkey: Ministry of Health
Study type Interventional

Clinical Trial Summary

This study evaluates the significance of differences in serum angiotensin converting enzyme and lysozyme levels of patients with ocular involvement of other autoimmune inflammatory and infectious diseases.

Description:

Increased serum levels of angiotensin converting enzyme and lysozyme are considered as inflammatory markers for diagnosis of sarcoidosis which is an autoimmune inflammatory disease. Sarcoidosis, ankylosing spondylitis and Behcet's disease are the most common autoimmune inflammatory diseases involving the eye.

Elevated serum angiotensin converting enzyme levels have also been reported in tuberculosis. Syphilis and tuberculosis are the most common infectious diseases involving the eye.

Recruitment information / eligibility
Status Recruiting
Enrollment 280
Est. completion date January 2017
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Both
Age group 9 Years to 86 Years
Eligibility Inclusion Criteria:

- Subjects have ocular inflammation diagnosed as sarcoidosis, ankylosing spondylitis, behcet's disease

- Subjects have ocular infection diagnosed as tuberculosis and syphilis

- Subjects have refractive errors only

Exclusion Criteria:

- Subjects using ACE inhibitors, systemic steroids, immunosuppressive or immunomodulatory therapies

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Intervention

Other:
• spectrophotometric assay
measurement of enzyme activity in the serum
• radial immunodiffusion
measurement of the precipitated ring diameters showing enzyme activity in the serum

Locations
Country Name City State
Turkey DunyaGoz hospital Tunus caddesi no.28 kavaklidere Cankaya Ankara

Sponsors (1)
Lead Sponsor Collaborator
Ozlem Sahin

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Birnbaum AD, Oh FS, Chakrabarti A, Tessler HH, Goldstein DA. Clinical features and diagnostic evaluation of biopsy-proven ocular sarcoidosis. Arch Ophthalmol. 2011 Apr;129(4):409-13. doi: 10.1001/archophthalmol.2011.52. — View Citation

Sen DK, Sarin GS. Immunoassay of serum muramidase (lysozyme) in ocular diseases. Indian J Ophthalmol. 1987;35(5-6):103-7. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Analysis of serum angiotensin converting enzyme level 1 day No
Secondary Analysis of serum lysozyme level 1 day No
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2